Please use this identifier to cite or link to this item:
Title: Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma.
Epworth Authors: Yannakou, Costas
Prince, Miles
Other Authors: Abeyakoon, Chathuri
van der Weyden, Carrie
Harrop, Sean
Khot, Amit
Keywords: PTCL
Haematopoietic Stem Cell Transplantation
Peripheral T-Cell Lymphomas (PTCLs)
Optimal Therapy
Hepatosplenic T-Cell Lymphoma (HSTCL)
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Complete Remission Rates
Progression-Free Survival (PFS)
Overall Survival (OS)
Anaplastic Large-Cell Lymphoma (ALCL)
Anaplastic Lymphoma Kinase (ALK)-Positive Subtype
Haematopoietic Stem Cell Transplantation (HSCT)
Angioimmunoblastic T-Cell Lymphoma (AITL)
Acute Graft Versus Host Disease (aGVHD)
American Society for Transplantation and Cellular Therapy (ASTCT)
Angioimmunoblastic T-Cell Lymphoma (AITL)
Autologous Stem Cell Transplantation (autoSCT)
Allogeneic Stem Cell Transplantation (alloSCT)
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE)
Enteropathy Associated T-Cell Lymphoma (EATL)
European Society for Bone and Marrow Transplantation (EBMT)
European Society for Medical Oncology (ESMO)
Myeloablative Conditioning (MAC)
Nordic Lymphoma Group-T-01 (NLG-T-01)
Non-Myeloablative Conditioning (NMAC)
Non-Relapse Mortality (NRM)
Prognostic Index for Peripheral T-Cell Lymphoma (PIT)
Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)
Reduced-Intensity Conditioning (RIC)
Relapsed and Refractory (RR)
Transplantation-Related Mortality (TRM)
Epworth Centre for Immunotherapies and Snowdome Laboratories
Molecular Oncology and Cancer Immunology
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Oct-2020
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
Citation: Cancers (Basel). 2020 Oct 26;12(11):3125.
Abstract: Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymphoma counterpart. Frequently aggressive in their clinical behaviour, clinicians are constantly challenged with low complete remission rates, early relapses and failure to achieve long-term responses despite aggressive first-line chemotherapy, resulting in poor overall survival in the majority of patients. There is currently no consensus regarding the optimal therapy for PTCL and treatment approaches are mainly derived from prospective phase II studies, registry data and retrospective studies. Despite its biological heterogeneity, a less than satisfactory "one-size-fits-all" approach has been adopted to date. Although its role remains controversial, for many years, haematopoietic stem cell transplantation has been adopted by clinicians with the aim of overcoming poor outcomes by consolidating responses. In this review, we aim to define the role of both autologous and allogeneic stem cell transplantation in PTCL in both frontline and salvage settings, especially in the context of recent advancements in this field. The electronic database MEDLINE (1998–2020) was searched to review the role of HSCT in PTCLs. Titles, keywords and abstracts of citations were reviewed and full copies of potentially suitable articles were assessed further. The following search strategy was used: ‘bone marrow transplantation’ OR ‘hematopoietic stem cell transplantation’ OR ‘stem cell transplantation’ AND ‘lymphoma, t-cell’ OR ‘t-cell, peripheral’ with limits to adults, English language AND Humans. On the basis of currently available data, HSCT remains an important therapeutic modality in the management of PTCLs in both the frontline and salvage settings, however the lack of good quality randomized data to guide management has resulted in lack of consensus and occasionally conflicting recommendations in the literature. The rapidly evolving changes in the diagnostic and therapeutic landscape, will necessitate an ongoing evaluation of the role of HSCT in the management of these heterogeneous diseases.
DOI: 10.3390/cancers12113125
PubMed URL:
ISSN: 2072-6694
Journal Title: Cancers (Basel)
Type: Journal Article
Affiliated Organisations: Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3000, Australia
Royal Mebourne Hospital, Melbourne, Victoria 3052, Australia
Type of Clinical Study or Trial: Clinical Trial
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.